March 3, 2017
Baxter International Inc. (NYSE: BAX) and ScinoPharm Taiwan, Ltd. (TWSE: 1789) last week announced a strategic partnership to develop, manufacture and commercialize five injectable generic drugs used in a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer, as well as medication to treat nausea and vomiting, common side effects of chemotherapy. The arrangement also provides Baxter the option to partner with ScinoPharm—one of the world’s leading active pharmaceutical ingredient (API) manufacturers—on as many as 15 additional injectable molecules.
Under the terms of the partnership, Baxter and ScinoPharm will collaborate on product development and manufacturing. Baxter will hold commercialization rights, with products included in the arrangement expected to launch beginning in 2020.
Current branded sales of the initial five products included in this partnership total more than US$4 billion annually. These products will join Baxter’s existing portfolio of generic injectable medications, which includes difficult-to-manufacture oncology drugs and a broad portfolio of standard-dose, ready-to-use premixed injectable products such as anti-infectives, analgesics and critical care medicines.
ScinoPharm has a 17-year history of manufacturing APIs for the global pharmaceutical industry. Under the arrangement, ScinoPharm will provide APIs for the initial five generic injectables, and Baxter and ScinoPharm will share manufacturing responsibilities, with the majority of the molecules to be manufactured at Baxter’s oncology drug manufacturing facility in Halle, Germany.
Read the press release.